NEW YORK, Nov. 12-Cephalon will use Pharsight's modeling and simulation methods to investigate new applications for Provigil, its narcolepsy treatment, Pharsight said today.
Cephalon has used Pharsight's systems before during clinical trials to help determine appropriate drug dosage for the treatment of sleep disorders.
With the expanded agreement, Cephalon now plans to use Pharsight's modeling techniques to predict dosages for the treatment of attention deficit hyperactivity disorder.
Financial details of the expanded agreement were not disclosed.
For further details, see the company statement.